This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Miura JT , Kroon HM , Beasley GM , Mullen D , Farrow NE , Mosca PJ , Lowe MC , Farley CR , Kim Y , Naqvi SMH , Potdar A , Daou H , Sun J , Farma JM , Henderson MA , Speakman D , Serpell J , Delman KA , Mark Smithers B , Coventry BJ , Tyler DS , Thompson JF , Zager JS
Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis
Ann Surg Oncol. 2019 Aug;26(8) :2486-2494
PMID: 30911949 URL: https://www.ncbi.nlm.nih.gov/pubmed/30911949
AbstractBACKGROUND: Isolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose regional chemotherapy to patients with locally advanced or in-transit melanoma located on a limb. The current international multicenter study evaluated the perioperative and long-term oncologic outcomes for patients who underwent ILI for stage 3B or 3C melanoma. METHODS: Patients undergoing a first-time ILI for stage 3B or 3C melanoma (American Joint Committee on Cancer [AJCC] 7th ed) between 1992 and 2018 at five Australian and four United States of America (USA) tertiary referral centers were identified. The primary outcome measures included treatment response, in-field (IPFS) and distant progression-free survival (DPFS), and overall survival (OS). RESULTS: A total of 687 first-time ILIs were performed (stage 3B: n = 383, 56%; stage 3C; n = 304, 44%). Significant limb toxicity (Wieberdink grade 4) developed in 27 patients (3.9%). No amputations (grade 5) were performed. The overall response rate was 64.1% (complete response [CR], 28.9%; partial response [PR], 35.2%). Stable disease (SD) occurred in 14.5% and progressive disease (PD) in 19.8% of the patients. The median follow-up period was 47 months, with a median OS of 38.2 months. When stratified by response, the patients with a CR or PR had a significantly longer median IPFS (21.9 vs 3.0 months; p < 0.0001), DPFS (53.6 vs 12.7 months; p < 0.0001), and OS (46.5 vs 24.4 months; p < 0.0001) than the nonresponders (SD + PD). CONCLUSION: This study is the largest to date reporting long-term outcomes of ILI for locoregionally metastatic melanoma. The findings demonstrate that ILI is effective and safe for patients with stage 3B or 3C melanoma confined to a limb. A favorable response to ILI is associated with significantly longer IFPS, DPFS, and OS.
Notes1534-4681 Miura, John T Kroon, Hidde M Beasley, Georgia M Mullen, Dean Farrow, Norma E Mosca, Paul J Lowe, Michael C Farley, Clara R Kim, Youngchul Naqvi, Syeda Mahrukh Hussnain Potdar, Aishwarya Daou, Hala Sun, James Farma, Jeffrey M Henderson, Michael A Speakman, David Serpell, Jonathan Delman, Keith A Mark Smithers, B Coventry, Brendon J Tyler, Douglas S Thompson, John F Zager, Jonathan S Journal Article United States Ann Surg Oncol. 2019 Aug;26(8):2486-2494. doi: 10.1245/s10434-019-07288-w. Epub 2019 Mar 25.